December 6, 2011
Bloomberg
Companies, trade groups, and lawyers representing diverse industrial sectors have filed more than two dozen legal briefs in a case set to be heard by the U.S. Supreme Court on December 7, 2011, on the validity of two patents held by Prometheus Laboratories that cover abstract thoughts or processes in the field of biological sciences. The patents involve methods for calibrating the proper dosage of drugs to treat autoimmune diseases, according to filings before the high court. “The claims have to do with diagnostic methods, but it has the potential to touch industries we don’t know about,” said Finnegan partner Erika Arner, who filed a brief on behalf of SAP, asking the court not to restrict software and computer patents. Because the court will be considering a fundamental question in patent law, subject matter patentability, the ruling has the potential to send “shock waves across all industries,” said Arner.
Media Mention
Finnegan Shortlisted for the 2024 Asian Legal Business Japan Law Awards
April 26, 2024
Commentary
April 11, 2024
Media Mention
Women in Business Law Americas Awards 2024: Three Finnegan Attorneys Shortlisted
April 7, 2024
Press Release
Finnegan and BMW Group Successfully Demolish Non-Practicing Entity NorthStar’s Efforts
April 3, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.